화학요법 유발 메스꺼움 및 구토 치료 시장 : 약물 종류별, 투여 경로별, 최종사용자별 - 세계 예측(2025-2030년)

The Chemotherapy Induced Nausea & Vomiting Treatment Market was valued at USD 2.94 billion in 2023, expected to reach USD 3.13 billion in 2024, and is projected to grow at a CAGR of 6.54%, to USD 4.58 billion by 2030.

The scope of the chemotherapy-induced nausea and vomiting (CINV) treatment market involves developing and distributing therapeutic interventions aimed at alleviating nausea and vomiting in cancer patients undergoing chemotherapy. This is crucial as CINV significantly impacts patients' quality of life and can hinder the effectiveness of cancer treatment due to non-compliance. These treatments are primarily applied in clinical settings, hospitals, and home care environments. Predominant end-users include healthcare providers, cancer treatment centers, and home care patients. Market growth is driven by increasing global cancer prevalence, advancements in treatment modalities, and heightened awareness about supportive care options for cancer patients. Latest opportunities include the development of novel therapeutic agents, expanding the use of combination therapies for enhanced efficacy, and leveraging digital health platforms for patient management and adherence improvement. Recommendations for market players include investing in research and development to create new pharmaceutical agents and supporting telemedicine initiatives to augment treatment accessibility and patient monitoring. However, the market faces challenges such as stringent regulatory requirements for new treatments, varying reimbursement policies across regions, and the high cost of medication development which can limit market penetration. Furthermore, patient-specific variability in treatment response necessitates personalized approaches, adding complexity to drug development and application. Innovation is likely to thrive in the formulation of personalized medicine strategies, artificial intelligence-driven predictive models for treatment side effects, and the integration of care management platforms. The nature of the CINV treatment market is competitive and dynamic, necessitating continuous adaptation to technology advancements and regulatory changes. Engaging in strategic partnerships and collaborations with biotech firms and research institutions may offer pathways to overcome existing limitations and secure a competitive edge through unique therapeutic offerings and enhanced patient-centric care solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chemotherapy Induced Nausea & Vomiting Treatment Market

The Chemotherapy Induced Nausea & Vomiting Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising global cancer incidence among the aging population and Increasing healthcare expenditures, amplify the need for CINV treatments.
  • Collaborations between pharmaceutical companies, research organizations, and healthcare providers facilitate the development and distribution of advanced CINV treatments.
  • Innovations in drug delivery technologies such as sustained-release formulations and transdermal patches, improve patient compliance and effectiveness of CINV treatments.
• Market Restraints
  • Lack of adequate training or awareness among healthcare providers regarding the latest and most effective CINV treatments
• Market Opportunities
  • Partnering with academic institutions, biotech companies, and cancer research organizations to accelerate the development of new treatments.
  • Expanding clinical trials and treatment strategies to include diverse patient populations to ensure broad applicability and effectiveness.
• Market Challenges
  • High R&D costs and financial risks involved in bringing new drugs to market, coupled with pricing and reimbursement issues

Porter's Five Forces: A Strategic Tool for Navigating the Chemotherapy Induced Nausea & Vomiting Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chemotherapy Induced Nausea & Vomiting Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chemotherapy Induced Nausea & Vomiting Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chemotherapy Induced Nausea & Vomiting Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chemotherapy Induced Nausea & Vomiting Treatment Market

A detailed market share analysis in the Chemotherapy Induced Nausea & Vomiting Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chemotherapy Induced Nausea & Vomiting Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chemotherapy Induced Nausea & Vomiting Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chemotherapy Induced Nausea & Vomiting Treatment Market

A strategic analysis of the Chemotherapy Induced Nausea & Vomiting Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Nausea & Vomiting Treatment Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group plc, Apotex Inc., Astellas Pharma Inc., Baxter International Inc., Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Fresenius Kabi AG, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Helsinn Healthcare SA, Lupin Limited, Merck & Co., Inc., Pfizer Inc, Practo Technologies Private Limited, TAIHO PHARMACEUTICAL CO., LTD., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Nausea & Vomiting Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Benzodiazepines, Cannabinoids, Corticosteroids, Dopamine Antagonists, NK1 Receptor Antagonists, and Serotonin Receptor Antagonists.
• Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal.
• Based on End User, market is studied across Cancer Treatment Centers, Home Care Settings, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising global cancer incidence among the aging population and Increasing healthcare expenditures, amplify the need for CINV treatments.
    • 5.1.1.2. Collaborations between pharmaceutical companies, research organizations, and healthcare providers facilitate the development and distribution of advanced CINV treatments.
    • 5.1.1.3. Innovations in drug delivery technologies such as sustained-release formulations and transdermal patches, improve patient compliance and effectiveness of CINV treatments.
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of adequate training or awareness among healthcare providers regarding the latest and most effective CINV treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Partnering with academic institutions, biotech companies, and cancer research organizations to accelerate the development of new treatments.
    • 5.1.3.2. Expanding clinical trials and treatment strategies to include diverse patient populations to ensure broad applicability and effectiveness.
  • 5.1.4. Challenges
    • 5.1.4.1. High R&D costs and financial risks involved in bringing new drugs to market, coupled with pricing and reimbursement issues
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Significant role of Benzodiazepines focusing on the mechanisms and effectiveness of different drug classes
  • 5.2.2. Route of Administration: Optimizing CINV treatment necessitates evaluation of injectable, oral, and transdermal routes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Drug Class

• 6.1. Introduction
• 6.2. Benzodiazepines
• 6.3. Cannabinoids
• 6.4. Corticosteroids
• 6.5. Dopamine Antagonists
• 6.6. NK1 Receptor Antagonists
• 6.7. Serotonin Receptor Antagonists

7. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral
• 7.4. Transdermal

8. Chemotherapy Induced Nausea & Vomiting Treatment Market, by End User

• 8.1. Introduction
• 8.2. Cancer Treatment Centers
• 8.3. Home Care Settings
• 8.4. Hospitals

9. Americas Chemotherapy Induced Nausea & Vomiting Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Chemotherapy Induced Nausea & Vomiting Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Chemotherapy Induced Nausea & Vomiting Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. AstraZeneca acquires Fusion Pharmaceuticals to accelerate radio conjugate cancer treatment advancements and expand oncology pipeline
  • 12.3.2. Glenmark Launches Injection to Combat Chemotherapy-Induced Nausea and Vomiting in India
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Acacia Pharma Group plc
• 2. Apotex Inc.
• 3. Astellas Pharma Inc.
• 4. Baxter International Inc.
• 5. Dr. Reddy's Laboratories Ltd.
• 6. Eisai Co., Ltd.
• 7. Fresenius Kabi AG
• 8. GlaxoSmithKline plc
• 9. Glenmark Pharmaceuticals Ltd.
• 10. Helsinn Healthcare SA
• 11. Lupin Limited
• 12. Merck & Co., Inc.
• 13. Pfizer Inc
• 14. Practo Technologies Private Limited
• 15. TAIHO PHARMACEUTICAL CO., LTD.
• 16. Teva Pharmaceutical Industries Ltd.